Mark Ultsch

发表

Antibodies specific for a segment of human membrane IgE deplete IgE-producing B cells in humanized mice.

Min Xu, Charles Eigenbrot, Meijuan Zhou, 2010, The Journal of clinical investigation.

Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.

Jane R Kenny, Michael Siu, Deepak Sampath, 2012, Journal of medicinal chemistry.

A pentacyclic aurora kinase inhibitor (AKI-001) with high in vivo potency and oral bioavailability.

Guy Georges, Elizabeth Blackwood, Christian Wiesmann, 2008, Journal of medicinal chemistry.

Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers

Ariana Peck, Shiuh-Ming Luoh, Steve Price, 2013, Nature.

A new regulatory switch in a JAK protein kinase

Charles Eigenbrot, Vickie Tsui, Paul Gibbons, 2011, Proteins.

Antiparallel conformation of knob and hole aglycosylated half-antibody homodimers is mediated by a CH2-CH3 hydrophobic interaction.

Charles Eigenbrot, M. Ultsch, C. Eigenbrot, 2014, Journal of molecular biology.

A class of 2,4-bisanilinopyrimidine Aurora A inhibitors with unusually high selectivity against Aurora B.

Jennafer Dotson, Christian Wiesmann, Jason Drummond, 2009, Journal of medicinal chemistry.

Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2.

Jane R Kenny, Philippe Bergeron, Charles Eigenbrot, 2012, Bioorganic & medicinal chemistry letters.

Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors.

Bohdan Waszkowycz, Jane R Kenny, Charles Eigenbrot, 2012, Journal of medicinal chemistry.

Structure of a phage display-derived variant of human growth hormone complexed to two copies of the extracellular domain of its receptor: evidence for strong structural coupling between receptor binding sites.

C. Schiffer, M. Ultsch, A. D. de Vos, 2002, Journal of molecular biology.

Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.

Jane R Kenny, Philippe Bergeron, Tian Jin, 2012, Journal of medicinal chemistry.

Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc

Leonard G. Presta, L. Presta, M. Ultsch, 2000, The Journal of Immunology.

Structural basis for high-affinity HER2 receptor binding by an engineered protein

L. Abrahmsén, M. Ultsch, T. Härd, 2010, Proceedings of the National Academy of Sciences.